Background: Antimicrobial resistance (AMR) is a growing global problem to which the ongoing COVID-19 pandemic may further contribute. With resources deployed away from antimicrobial stewardship, evidence of substantial pre-emptive antibiotic use in COVID-19 patients and indirectly, with deteriorating economic conditions fuelling poverty potentially impacting on levels of resistance, AMR threat remains significant. Main body: In this paper, main AMR countermeasures are revisited and priorities to tackle the issue are re-iterated. The need for collaboration is stressed, acknowledging the relationship between human health, animal health and environment (“One Health” approach). Among the stated priorities, the initiative by the European Medicines Regulatory Network to further strengthen the measures in combatting AMR is highlighted. Likewise, it is asserted that other emerging health threats require global collaboration with the One Health approach offering a valuable blueprint for action. Conclusion: The authors stress the importance of an integrated preparedness strategy to tackle this public health peril.
Following the start of the COVID-19 vaccination campaign, the adverse events of myocarditis and pericarditis were linked mainly to mRNA COVID-19 vaccines by the regulatory authorities worldwide. COVID-19 vaccines have been administered to several million people and the risk of myocarditis post COVID-19 vaccination has been characterised in great detail. At the present time the research data available are scarce and there is still no clear understanding of the biological mechanism/s responsible for this disease. This manuscript provides a concise overview of the epidemiology of myocarditis and the most prominent mechanistic insights in the pathophysiology of the disease. Most importantly it underscores the needed next steps in the research agenda required to characterize the pathophysiology of this disease post-COVID-19 vaccination. Finally, it shares our perspectives and considerations for public health.
The in vitro hollow fiber system model has been qualified by the European Medicines Agency as a methodology for use in support of selection and development of antituberculosis regimens. More data are expected to be generated in the future to further characterize its value.
Safety and efficacy of vaccines against the SARS-CoV-2 coronavirus has been demonstrated in clinical trials and next by their real world use through the course of the ongoing COVID-19 pandemic. However, very rare adverse events have been detected post-authorization in certain parts of the world. This meeting report summarizes an EMA workshop’s discussion on the epidemiology, clinical presentation and biology of thrombosis with thrombocytopenia syndrome after adenovirus vector COVID-19 vaccination. General agreement was reached by international regulators, scientists and developers on the steps needed to fill the gaps in the characterization of this new syndrome. In particular, actions should be taken to improve the post-vaccination surveillance activities in low and middle income countries and investigate potential genetic predisposition factors.
The global clinical research ecosystem faced highs and lows during the COVID-19 pandemic. Key issues included research waste from poor-quality trials and fragmented regulatory and ethical reviews. Streamlining and harmonising these review processes is crucial for efficient, robust, and timely multinational trials, ensuring rigorous scientific standards, proper safety, and ethical oversight. Robust regulatory and ethics review systems thrive on continuous learning and efficient processes, crucial for high-quality research. Enhancing trial design and implementation, and guiding innovative approaches including decentralised trials and patient-centric designs are essential for the regulatory and ethics authorities to advance public health. These approaches are built on the principles of global guidance outlined in International Coalition for Harmonization Good Clinical Practice guidelines and the WHO guidance for best practice for clinical trials. To realise the agreed vision at the first WHO Global Clinical Trials Forum in 2023, a panel of international experts in clinical research, including representatives from national and regional regulatory and ethics authorities, proposes key actions to improve coordination and streamlining of regulatory and ethics review. The actions emphasise: leveraging existing trial networks and capacity-building initiatives; advancing joint and parallel regulatory and ethics reviews and single national ethics review; improving transparency on approval requirements; simplifying and standardising informed consent forms and processes; and developing mechanisms to improve efficiency for trial site contracting as well as exportation and importation of investigational products for trials. The proposed actions for the reform are urgent and key to generate evidence to enable access to safe and effective interventions for populations most in need.